About Prestwick Chemical
Prestwick Chemical is a Healthcare company based in Illkirch-graffenstaden (France) founded in 1999, and was acquired by Domain Therapeutics in December 2019. It provides chemical screening libraries and customized medicinal chemistry services to drug developers. Its chief executive, as recorded, is Deborah Rathjen. Prestwick Chemical offers products and services including Prestwick Chemical Library, Prestwick Oncombo Library, and Custom Synthesis. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry.
Company details
Prestwick Chemical is a French CRO. It offers chemical screening libraries and customised medicinal chemistry services to accelerate early drug development. It provides medchem services such as hit discovery, hit validation, hit-to-lead, lead optimization, computational chemistry and custom synthesis services. Prestwicks chemical libraries can be used to find stem cell growth modulators and also for Repurposing Repositioning. It claims that it has helped in bringing 1 NCE to the market, also in bringing 10 NCEs to the clinic and 8 are currently in the preclinical phase.
- Headquarters Illkirch-graffenstaden, France
- Stage Acquired
- SectorsHealthcare
- Website prestwickchemical.com
- Social LinkedIn X
- Acquired by Domain Therapeutics (Dec 2019)
- Investors
- Acquired byDomain Therapeutics
(Dec 2019)
Products & Services of Prestwick Chemical
Prestwick Chemical offers a comprehensive portfolio of products and services, including Prestwick Chemical Library, Prestwick Oncombo Library, and Custom Synthesis.
Collection of 1760 FDA-approved drugs for early drug discovery screening.
Specialized library for combination drug testing in research.
Provides analogues and original compounds for drug development needs.
Investors in Prestwick Chemical
Prestwick Chemical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Domain Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
GPCR-targeted drug candidates for immuno-oncology and inflammation are developed. | 2008 | domaintherapeutics.com | Strasbourg, France |
Investor details for Prestwick Chemical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prestwick Chemical
1 people are tracked at Prestwick Chemical (1 in leadership).
| Name | Role | Group |
|---|---|---|
Deborah Rathjen | CEO | Leadership |
Complete people profiles for Prestwick Chemical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prestwick Chemical
2 dated milestones of Prestwick Chemical across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Prestwick Chemical is founded.
- Exit Acquired by Domain Therapeutics.
Web traffic of Prestwick Chemical
The website of Prestwick Chemical (prestwickchemical.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 24.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prestwick Chemical
Complete news archive for Prestwick Chemical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prestwick Chemical
Prestwick Chemical was founded in 1999.
Prestwick Chemical is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Deborah Rathjen is the CEO of Prestwick Chemical, as recorded in our data.
Prestwick Chemical is a French CRO. It offers chemical screening libraries and customised medicinal chemistry services to accelerate early drug development. It provides medchem services such as hit discovery, hit validation, hit-to-lead, lead optimization, computational chemistry and custom synthesis services. Prestwicks chemical libraries can be used to find stem cell growth modulators and also for Repurposing Repositioning. It claims that it has helped in bringing 1 NCE to the market, also in bringing 10 NCEs to the clinic and 8 are currently in the preclinical phase.
Prestwick Chemical offers Prestwick Chemical Library, Prestwick Oncombo Library, and Custom Synthesis.
Prestwick Chemical has 1 investor. Key investors include Domain Therapeutics.
Yes. Prestwick Chemical was acquired by Domain Therapeutics in December 2019.

